Myelofibrosis and related myeloproliferative neoplasms
Research activity includes primary myelofibrosis, post-polycythaemia vera myelofibrosis, and post-essential thrombocythaemia myelofibrosis, with attention to disease burden driven by splenomegaly, constitutional symptoms, and progressive marrow dysfunction.
- Primary myelofibrosis
- Post-polycythaemia vera myelofibrosis
- Post-essential thrombocythaemia myelofibrosis
The sponsor’s clinical focus in these disorders centres on treatment areas where symptom control and reduction of spleen enlargement are key therapeutic needs.
VEXAS syndrome and autoinflammatory disease
Clinical research also extends to VEXAS syndrome, a complex autoinflammatory condition associated with systemic inflammation, hematologic abnormalities, and multisystem involvement.
- VEXAS syndrome
- Autoinflammatory manifestations
- Systemic inflammatory disease
This area reflects interest in conditions where inflammatory control and improvement of disease-related symptoms are central therapeutic goals.
Symptom burden and spleen-related outcomes
Trials supported by the sponsor place emphasis on clinically meaningful outcomes such as spleen volume reduction, total symptom score improvement, and overall relief of disease-associated discomfort.
- Spleen volume reduction
- Total symptom score
- Symptom burden
These endpoints align with therapeutic areas where changes in organ enlargement and patient-reported symptoms are important measures of benefit.
Hematology and immune-mediated disorders
The sponsor’s portfolio sits at the intersection of hematology and immune-mediated inflammatory disease, addressing disorders that combine abnormal blood cell biology with inflammatory pathology.
- Hematologic disease
- Immune-mediated inflammation
- Bone marrow disorders
Research in these domains supports clinical development for conditions with overlapping hematologic and inflammatory features.
